<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03933280</url>
  </required_header>
  <id_info>
    <org_study_id>2019/3/25/9</org_study_id>
    <nct_id>NCT03933280</nct_id>
  </id_info>
  <brief_title>Conscious Sedation for Cataract Operations Under Topical Anaesthesia</brief_title>
  <official_title>Nalbuphine/Dexmedetomidine Versus Nalbuphine/Propofol Conscious Sedation for Cataract Extraction Under Topical Anaesthesia: A Double‑Blind Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menoufia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menoufia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Topical anaesthesia of the eye for ophthalmologic procedures avoids pain and discomfort of
      local anaesthetic injection in the peribulbar or retrobulbar block so that patient
      comfortability is achieved. Sedation during topical anaesthesia of the eye is mostly required
      to achieve anxiolysis, amnesia and keeping the patient calm all through the procedure. In the
      present study, the investigators will investigate the effect of nalbuphine/dexmedetomidine
      versus nalbuphine/propofol on the sedation as a primary outcome, intra-operative,
      postoperative analgesia, vital signs, patient and surgeon satisfaction and side effects as
      secondary outcomes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In both groups, the patients will receive i.v. nalbuphine 50 μg/kg. Patients in group D, will
      receive an i.v. loading dose of dexmedetomidine 1 μg/kg over 10 min followed by a maintenance
      infusion of 0.5 μg/kg/h. Patients in group P, will receive a bolus i.v. dose of propofol 0.5
      mg/kg followed by an infusion started at 0.025 mg/kg/min .If sedation score was &lt;3, rescue
      sedation with boluses of midazolam 0.01 mg/kg will be given. If the patient complained of
      pain (Numerical verbal pain rating scale ≥3) during the surgery, i.v. fentanyl 50 μg will be
      given as an intra-operative rescue analgesic and the surgeon will be instructed to use
      additional topical local anaesthetic eye drops if appropriate. After the completion of
      surgery, all infusions will be stopped, and the patients will be shifted to the
      postanaesthetic care unit (PACU) to be monitored for 2 hours before discharge.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>An independent anaesthesiologist not involved in the study will open the randomisation envelope just before the premedication and will prepare the appropriate drug-filled syringes according to the code and will not take part in the management and observations. (Syringes and infusion lines will be concealed by wrapping with an aluminium foil). A blinded investigator that will not be involved in the anaesthetic management of the patients, will collect the intra-operative and postoperative data.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sedation score</measure>
    <time_frame>perioperative</time_frame>
    <description>The degree of sedation assessed by Ramsay sedation score(1 = anxious, agitated, restless;2 = cooperative, oriented, tranquil; 3 = responds to commands only; 4 = brisk response to light glabellar tap or loud noise; 5 = sluggish response to light glabellar tap or loud noise; 6 = no response), score of (1) means inadequate sedation. Score (2 to 4) indicates acceptable sedation. Score (5) or (6) excessive sedation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>perioperative</time_frame>
    <description>Heart rate in beats/minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial blood pressure</measure>
    <time_frame>perioperative</time_frame>
    <description>Mean arterial blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>perioperative</time_frame>
    <description>Arterial oxygen saturation as a percentage of the total haemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesia</measure>
    <time_frame>perioperative</time_frame>
    <description>Measured by Numerical Pain Rating scale where the patient verbally rates pain from 0 &quot;no pain&quot; to 10 &quot;worst imaginable pain&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Conscious Sedation</condition>
  <arm_group>
    <arm_group_label>Group P</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nalbuphine/propofol group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Droup D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nalbuphine/dexmedetomidine group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalbuphine</intervention_name>
    <description>i.v. nalbuphine bolus of 50 μg/kg.</description>
    <arm_group_label>Droup D</arm_group_label>
    <arm_group_label>Group P</arm_group_label>
    <other_name>Nalbuphine bolus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>A bolus i.v. dose of propofol 0.5 mg/kg followed by an infusion of 0.025 mg/kg/min</description>
    <arm_group_label>Group P</arm_group_label>
    <other_name>propofol infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>i.v. loading dose of dexmedetomidine 1 μg/kg over 10 min followed by a maintenance infusion of 0.5 μg/kg/h.</description>
    <arm_group_label>Droup D</arm_group_label>
    <other_name>Dexmedetomidine infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benoxinate Hydrochloride 0.4% Eye Drops</intervention_name>
    <description>Benoxinate hydrochloride 0.4% eye drops instilled twice, 5 minutes apart.</description>
    <arm_group_label>Droup D</arm_group_label>
    <arm_group_label>Group P</arm_group_label>
    <other_name>Topical anaesthesia of the eye</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both genders,

          -  20 and 65 years,

          -  American Society of Anesthesiologists (ASA) physical status I and II,

          -  Scheduled for cataract extraction surgery under topical anaesthesia.

        Exclusion Criteria:

          -  Known allergy to local anaesthetics,

          -  Allergy to study drugs,

          -  Second or third-degree heart block,

          -  Alcohol or drug abuse

          -  Morbid obesity, pregnant and lactating females,

          -  Patients with severe cardiac, renal and hepatic disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abd-Elazeem A Elbakry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Associate professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Cairo</city>
        <state>Shebin El-kom</state>
        <zip>32511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Menoufia University</investigator_affiliation>
    <investigator_full_name>Abd-Elazeem Abd-Elhameed Elbakry</investigator_full_name>
    <investigator_title>Associate professor of anaesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Nalbuphine</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Benoxinate</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

